Filing Flows › Stoke Therapeutics (STOK) › Q3 2026
Stoke Therapeutics (STOK) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 3, 2026
Stoke Therapeutics (STOK) reported revenue of $11.3M for the third quarter 2026 (Q3 2026), +6% from a year earlier and +21% from the quarter before. Operating margin was -686.9%, net loss $73.6M (654.3% of revenue).
Stoke Therapeutics, Q3 2026: revenue $11.3M (+6% year over year), operating margin -686.9%, net loss $73.6M, operating cash flow −$62.7M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $11.3M | +21% | +6% |
| Operating profit | −$77.3M | — | — |
| Net earnings | −$73.6M | — | — |
| Operating cash flow | −$62.7M | — | — |
What changed
Revenue was $11.3M in Q3 2026, up 6% year over year and up 21% from the previous quarter.
Operating costs exceeded revenue by $77.3M, an operating margin of -686.9%. Total costs grew 65% against revenue growth of 6%. The fastest-growing cost line was SG&A (+79%). The quarter ended with a net loss of $73.6M, wider than the previous quarter's $61.6M loss.
Operating cash flow was −$62.7M. Non-cash charges added back $455K of depreciation and $11.0M of share-based compensation. Capital expenditures of $2.9M exceeded it, leaving free cash flow of −$65.5M.
Questions
What was Stoke Therapeutics' revenue in the third quarter 2026?
Stoke Therapeutics (STOK) reported revenue of $11.3M for the third quarter 2026 (Q3 2026), +6% from a year earlier and +21% from the quarter before.
Was Stoke Therapeutics profitable in the third quarter 2026?
Operating loss was $77.3M (-686.9% of revenue) and net loss $73.6M.
Source: Stoke Therapeutics 10-Q on SEC EDGAR.